KRAS and neoplasm: Although inhibition of HPK1 kinase activity has been shown to enhance T cell activation and may potentially improve tumor response to immunotherapies for patients with solid tumors, it may also promote the activation of Ras and its downstream signaling and an immunosuppressive microenvironment as well as enhance the tumor development mediated by oncogenic mutant Kras.